Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Burn Injuries01:22

Burn Injuries

4.9K
Burn injuries occur when the skin and underlying tissues are damaged due to exposure to heat, electricity, chemicals, radiation, or friction. They can vary in severity, from minor superficial burns to severe deep burns that can be life-threatening.
The damage results in the death of skin cells, which can lead to a massive loss of fluid. Dehydration, electrolyte imbalance, and renal and circulatory failure follow, which can be fatal. Burn patients are treated with intravenous fluids to offset...
4.9K
Skin Diseases and Disorders01:23

Skin Diseases and Disorders

6.1K
Skin is the first line of defense and encounters a variety of microbes. Some pathogenic strains are often the cause of a broad range of infections of the skin and other body systems. These conditions can affect people of all ages and may have different causes, including genetic factors, infections, autoimmune reactions, environmental factors, and lifestyle choices.
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
6.1K
Infection01:20

Infection

13.9K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
13.9K
Skin Cancer01:30

Skin Cancer

6.5K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
6.5K
Blinding01:11

Blinding

4.0K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
4.0K
Standard Precaution01:26

Standard Precaution

3.3K
Standard precautions are the minimum infection control safeguards used while caring for all patients, irrespective of their disease condition. They help prevent the spread of common infectious microorganisms to healthcare workers, patients, and visitors in all healthcare settings.
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond Hematology-Current Insights into Chimeric Antigen Receptor (CAR) T-Cell Therapy for Skin and Connective Tissue Disorders.

Cells·2026
Same author

Observations of dystrophic epidermolysis bullosa patients with collagen VII NC2 truncation provide new insights into anchoring fibril assembly.

Matrix biology : journal of the International Society for Matrix Biology·2026
Same author

An evaluation of prademagene zamikeracel for the treatment of recessive dystrophic epidermolysis bullosa.

Expert opinion on biological therapy·2026
Same author

Prademagene zamikeracel for recessive dystrophic epidermolysis bullosa wounds (VIITAL): a two-centre, randomised, open-label, intrapatient-controlled phase 3 trial.

Lancet (London, England)·2025
Same author

Correction to: Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.

American journal of clinical dermatology·2025
Same author

Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa.

American journal of clinical dermatology·2025

Related Experiment Video

Updated: Mar 18, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K

Practice and Educational Gaps in Blistering Disease.

Nazanin Ehsani-Chimeh1, M Peter Marinkovich2

  • 1Department of Dermatology, Stanford University School of Medicine, 269 Campus Drive, CCSR Building, Room 2145, Stanford, CA 94305-5168, USA.

Dermatologic Clinics
|July 2, 2016
PubMed
Summary
This summary is machine-generated.

Managing autoimmune bullous diseases requires halting blistering while minimizing corticosteroid side effects. Steroid-sparing agents, rituximab, and intravenous immunoglobulin are key, alongside vigilant side effect monitoring for long-term patient care.

Keywords:
AutoimmunityBlisteringBullousPemphigoidPemphigus

More Related Videos

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.6K
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

1.3K

Related Experiment Videos

Last Updated: Mar 18, 2026

Granulocyte-dependent Autoantibody-induced Skin Blistering
12:23

Granulocyte-dependent Autoantibody-induced Skin Blistering

Published on: October 12, 2012

11.0K
A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
11:17

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo

Published on: August 11, 2018

12.6K
A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
07:22

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis

Published on: March 14, 2025

1.3K

Area of Science:

  • Immunology
  • Dermatology
  • Internal Medicine

Background:

  • Autoimmune bullous diseases (AIBD) present diagnostic challenges, often leading to delayed or inaccurate diagnoses and increased patient morbidity.
  • Effective management of AIBD is crucial to control disease activity and prevent long-term complications.

Purpose of the Study:

  • To outline the principles and essential tools for managing autoimmune bullous diseases.
  • To emphasize the importance of minimizing medication side effects, particularly from corticosteroids.

Main Methods:

  • Review of current therapeutic strategies for autoimmune bullous diseases.
  • Discussion of the role of systemic steroids, steroid-sparing agents, rituximab, and intravenous immunoglobulin.
  • Emphasis on the critical need for surveillance of drug side effects.

Main Results:

  • Delayed diagnosis in AIBD contributes significantly to patient morbidity.
  • Minimizing corticosteroid side effects is paramount in AIBD management.
  • Systemic steroids and steroid-sparing agents are essential therapeutic tools.
  • Rituximab and intravenous immunoglobulin are increasingly utilized earlier in treatment regimens.

Conclusions:

  • Effective management of autoimmune bullous diseases necessitates a balanced approach, halting disease activity while mitigating treatment-related toxicity.
  • Judicious use of systemic corticosteroids, steroid-sparing agents, and newer biologics like rituximab is vital.
  • Long-term patient care requires comprehensive understanding and monitoring of potential drug side effects.